Concepedia

Keith S. Kanik

KS

Statistics

Publications

36

Citations

6.8K

H-Index

25

Active since

1996

Affiliations

Pfizer (United States)(Current)

Metroplex Clinical Research Center

Pfizer (Canada)

University of Oxford

Swedish Medical Center

Keith S. Kanik is an author at Pfizer (United States) specializing in rheumatology, medicine, and pharmacotherapy.

Publications per year

1996–2024

36

Publications

36

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text

, , +15

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

, , +12

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

Philip J. Mease, Stephen Hall, Oliver FitzGerald et al. · New England Journal of Medicine · 2017 · 560 citations

, , +14

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo et al. · New England Journal of Medicine · 2017 · 508 citations · Full text

, , +14

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese et al. · Arthritis & Rheumatism · 2011 · 379 citations

, , +15

1–5 of 36